메인비쥬얼
Group Introduction
메인 컨텐츠
News
| Title | Huons Meditech Participates in MEDICA 2025 in Germany | |||
|---|---|---|---|---|
| User | PR | Date | 2025-11-20 | |
| Attachment | ||||
|
Huons Meditech Participates in MEDICA 2025 in Germany - CE-MDR certified Dermashine line draws strong attention - - “Strengthening global presence and expanding new partnerships” -
▲(Photo Description) Huons Meditech recently participated in ‘MEDICA 2025,’ the international medical device exhibition held in Düsseldorf, Germany. On the photo, a representative of Huons Meditech is presenting ‘Dermashine’ series to the exhibition participants.
Huons Meditech, a medical device
subsidiary of Huons Group, showcased its flagship products, including the
‘Dermashine’ series, at one of the world’s leading medical exhibitions.
Huons Meditech (CEO Changwoo Ha)
announced on the 20th that it took part in ‘MEDICA 2025,’ held in Düsseldorf,
Germany, from November 17.
‘MEDICA’ is one of the world’s
largest medical device exhibitions, with more than 5,000 companies from over 70
countries participating annually. It is widely recognized as a key global
platform to explore the latest technologies and innovations in the medical
device sector.
At this year’s exhibition, Huons
Meditech strengthened its global network across Europe, the Middle East, and
Asia, while actively promoting its products and brand in the medical and
aesthetic device markets.
During MEDICA 2025, the company
highlighted the excellence of various medical devices, including its Dermashine
product lineup (Dermashine Pro and Dermashine Balance). Dermashine is a
globally proven aesthetic medical device brand with over 20,000 units sold
worldwide, featuring highly precise drug delivery technology and a
user-friendly interface. In August, the Dermashine series became the first
electrically powered drug delivery device developed by a Korean company to
receive CE-MDR certification (Medical Device Regulation). Since then, the
company has actively promoted its performance through campaigns emphasizing the
importance of using genuine needles.
The extracorporeal shockwave
lithotriptor ‘URO-UEMXD,’ which combines a shockwave head and ultrasound in an
in-line structure, also attracted significant attention. The URO-UEMXD is the
first Korean-made device to combine these two components in a straight in-line
configuration, overcoming the limitations of conventional X-ray–based stone
localization systems. Huons Meditech also showcased additional products
including the endoscope reprocessor ‘HUEN DR-02,’ further highlighting the
breadth of its medical device portfolio.
CEO Changwoo Ha stated, “Our
participation in MEDICA 2025 has strengthened our presence in the European
market and created new opportunities for global collaboration. We will continue
to enhance our competitiveness in the global medical device industry through
ongoing technological innovation and quality advancement.” Huons Meditech continues to lay the groundwork for European market expansion through CE-MDR certification and is actively pursuing new partnerships not only in Europe but also across the Middle East and Asia by promoting its technological excellence and product competitiveness.
|
||||
| Number | Title | Date | Read |
|---|---|---|---|
| 92 | Huons Global Reports FY2025 Results, Revenue of KRW 847.5 Billion.. | 2026-02-13 | 89 |
| 91 | Huonslab on Track for Recombinant Human Hyaluronidase ‘HYDIZYME.. | 2026-02-11 | 116 |
| 90 | Huons Meditech Showcases at ‘WHX Dubai 2026’, Accelerating Ex.. | 2026-02-10 | 102 |
| 89 | PanGen Biotech Announces FY2025 Results, Revenue of KRW 13.42 Bil.. | 2026-02-03 | 151 |
| 88 | Huons Signs Distribution Agreement with Rappeler for Vitamin C an.. | 2026-01-30 | 203 |
| 87 | Humedix Celebrated a Symposium to Mark the Launch of Three Types .. | 2026-01-22 | 346 |
| 86 | Humedix Announces Syrian Approval for Three Types of HA Filler .. | 2026-01-12 | 379 |
| 85 | Huons BioPharma Secures NMPA Approval for Type A Botulinum Toxin .. | 2026-01-09 | 537 |
| 84 | Huons Group Kicks Off New Year with Employees, “New Beginning f.. | 2026-01-06 | 358 |
| 83 | Huonslab has submitted the Biologics License Application for Reco.. | 2025-12-22 | 731 |



